Charles Sidoti

Charles Sidoti serves as Chief Technology Officer at Brixton Biosciences. Brixton Biosciences operates in the research sector with approximately 23.0 employees. The company is headquartered in Cambridge, Massachusetts.

Industry & Role Insights

• • MessageCEO tracks 2,961 executives in the research sector.
• • 3,781 executive contacts are available in Massachusetts.
• • Our database includes 201,468 c suite-level executives.

Gmail Google Apps Amazon AWS Google Tag Manager Mobile Friendly Google Font API Remote

biotechnology research neural ice pain management injectable therapy opioid-free treatment long-lasting pain relief chronic pain clinical research pain relief injections drug-free solution targeted pain control pain desensitization orthopedic pain acute pain treatment fda breakthrough device designation investigational device nih heal initiative pain control technology cryoneurolysis pain sensitivity reduction knee osteoarthritis post-operative pain patient-centric care drug addiction prevention pain relief efficacy surgery recovery pain therapy chronic illness management non-addictive treatment innovative pain solution clinical trial medical innovation safety & effectiveness non-pharmacological treatments research partnerships healthcare advancement pain relief innovation injectable cold energy brixton biosciences academic research pain specialists treatment advancements clinical development injectable anesthetics pain control solutions reinvent pain management medical technology transformative pain therapy

SN

Srikanth Nandiraju Chief Technology Officer at 1Cell.Ai Inc.

SD

Surinnder Dang Chief Business Officer at 1Cell.Ai Inc.

M

Mark Chief Executive Officer at 23Strands

IT

Ilia Tikhomirov Chief Executive Officer at 35Pharma

AD

Alistair Draffan Chief Executive Officer at 360biolabs Pty Ltd

Outreach Guidance — research Sector

Executives like Charles Sidoti in the research sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Brixton Biosciences.

Charles Sidoti's Position in the MessageCEO Database

• •Charles Sidoti is 1 of 1 verified executive contact we track at Brixton Biosciences.
• •2,871 verified executive contacts in research are in the MessageCEO database.
• •3,577 verified executive contacts in Massachusetts are in the database.
• •36 verified contacts work at research companies in the 23.0 employee range (same size as Brixton Biosciences).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated August 2026.

How do I reach Charles Sidoti directly?

Charles Sidoti's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Technology Officer at Brixton Biosciences. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Charles Sidoti work for?

Charles Sidoti is Chief Technology Officer at Brixton Biosciences, a company in the research sector with 23.0 employees. The company is based in Cambridge, Massachusetts.

Can I pitch or sell to Charles Sidoti?

As Chief Technology Officer at Brixton Biosciences, Charles Sidoti is a key decision-maker in the research sector. MessageCEO Pro gives you verified email to reach Charles Sidoti directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Charles Sidoti in?

Charles Sidoti works in the research industry as Chief Technology Officer at Brixton Biosciences. MessageCEO provides verified contact information for executives across all major industries.

Is Charles Sidoti's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Charles Sidoti's profile is kept up-to-date with the latest available information.

Last updated: August 1, 2026